EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Werewolf Therapeutics's Enterprise Value is $-1.40 Mil.
Werewolf Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-59.98 Mil. Therefore, Werewolf Therapeutics's EV-to-FCF for today is 0.02.
The historical rank and industry rank for Werewolf Therapeutics's EV-to-FCF or its related term are showing as below:
HOWL'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.63 Med: -0.07 Max: 1.62
Current: 0.02
During the past 6 years, the highest EV-to-FCF of Werewolf Therapeutics was 1.62. The lowest was -5.63. And the median was -0.07.
HOWL's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 6.33
vs HOWL: 0.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Werewolf Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Werewolf Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's EV-to-FCF falls into.
Werewolf Therapeutics's current Enterprise Value is $-1.40 Mil.
Werewolf Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Werewolf Therapeutics's PE Ratio (TTM) for today is calculated as:
Werewolf Therapeutics's share price for today is $1.14.
Werewolf Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Werewolf Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Werewolf Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HOWL has been successfully added to your 